Purpose

The goal of this clinical trial is to follow the progress of wounds in those with venous leg ulcers and diabetic foot ulcers while using an absorbent dressing called Mepilex Up. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit. Participants will be asked to wear Mepilex Up dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Signed consent to participate (including consent for digital imaging) - Adult aged ≥18 years - Diagnosed with a chronic, exuding VLU or DFU - Exudate amount moderate to large - Wound size from 3 cm2 to 30 cm2 for VLU and ≥1 cm2 for DFU, as determined by the clinician - For VLU: ABPI (within 3 months) > 0.7. If ABPI > 1.4, then big toe pressure > 60 mmHg is required or an alternative measurement verifying normal distal arterial flow - For VLU: Willing to be compliant with compression therapy

Exclusion Criteria

  • Infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at enrollment - Circumferential wound - Known allergy/hypersensitivity to the materials of the dressing - Patients participating in the DIPLO NBF study - Use of wound fillers

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
The model is a prospective, open, multi-center, interventional, non-comparative investigation with the aim to follow exuding chronic wound progression for 6 weeks according to local standard of care.
Primary Purpose
Supportive Care
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Supportive Care with Mepilex Up
All Subjects will use a soft, silicone, non-bordered, adhesive, foam dressing called Mepilex Up as the absorbent primary dressing.
  • Device: Mepilex Up
    Mepilex Up is a highly conformable dressing that absorbs both low and high viscous exudates, maintains a moist wound environment and minimises the risk of maceration. The dressing has a Safetac® wound contact layer that is a unique adhesive technology. It minimises pain to patients and trauma to wounds and the surrounding skin at dressing removal. Mepilex Up consists of: - a soft silicone wound contact layer (Safetac) - a flexible absorbent pad of compressed polyurethane foam - an outer polyurethane film which is breathable but waterproof Dressing material content: Silicone, polyurethane

Recruiting Locations

Center for Clinical Research, Inc.
Castro Valley, California 94546
Contact:
Gayana Sarkisova, CCRC
800-363-1069
gayana@ccr-trials.com

Felix Sigal, DPM
Los Angeles, California 90010
Contact:
Maira Jackson, MA
maira@lafootpain.com

University of Miami
Miami, Florida 33125
Contact:
Aliette Espinosa
305-689-3376
a.espinosa2@med.miami.edu

Serena Group Research Institute
Pittsburgh, Pennsylvania 15222
Contact:
Laura Serena
412-335-0764
lserena@serenagroups.com

More Details

Status
Recruiting
Sponsor
Molnlycke Health Care AB

Study Contact

Janet Kandrevas, MD, MS
734-358-2174
janet.kandrevas@molnlycke.com

Detailed Description

This investigation is designed as a prospective, open, multi-center, interventional, non-comparative investigation with the aim to follow exuding chronic wound progression for 6 weeks according to local standard of care. Wound progress is a summary endpoint of the total effect of treatment using Mepilex Up as the absorbent dressing and includes the changes in an objectively measured wound area and subjectively evaluated wound condition. Two indications will be included: Venous Leg Ulcers (VLU) and Diabetic Foot Ulcers (DFU). A total of n=68 participants, approximately 34 per indication, will be recruited at up to 8 centers in the US. There will be a total of seven (7) visits to the investigation site for participants during the treatment period: baseline, followed by weekly visits up to six (6) weeks post baseline. During visits, evaluations will be performed to assess wound progression and status, wound dressing properties, as well as Subject pain, comfort, and quality of life. Safety will be assessed at all visits. One target wound per participant will be included in this investigation.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.